The use of low-molecular-weight heparin (LMWH) can lead to major life threatening complications, including hematomas. Abdominal wall muscle hematomas are rarely fatal, and encompass a wide spectrum of severity depending on size, etiology, and associated complications; but because of their rarity may be misdiagnosed clinically. We report a fatal case of an 80-year-old female who received LMWH after an episode of pulmonary thromboembolism and was subsequently diagnosed with a large right abdominal wall hematoma complicated with hypovolemic shock and acute kidney injury.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ⓒ 2014 Korean Society of Critical Care Medicine Low-molecular-weight heparin (LMWH) is increasingly used and has numerous indications, such as atrial fibrillation, acute coronary syndrome, thrombosis, and pulmonary embolism. [1, 2] Moreover, LMWH is widely used to prevent deep-vein thrombosis in patients undergoing hip or knee surgery that require prolonged bed rest. [3] While the cost is a higher than that of comparable oral medications, LMWH is effective and safe for use in outpatient settings after proper patient education because it is unnecessary to check prothrombin time (PT) with the international normalized ratio (INR) or activated partial thromboplastin time required of coumadin and heparin. Although the rate of severe adverse reactions is relatively low compared to other oral agents, LMWH can cause lethal bleeding complications, which may lead to death, including those from abdominal wall hematomas. [4] An abdominal wall hematoma under LMWH use is an uncommon condition, but it can occur particularly in patients with thin abdominal walls, such as elderly females or patients with a low body mass index. The risk is also greater with abdominal wall straining due to coughing or vomiting, in pregnancy, and in individuals taking other antiplatelet agents and/or anticoagulants. [5] [6] [7] We describe a fatal case of an 80-year-old female recently diagnosed with a cerebral infarction, who was undergoing LMWH therapy for pulmonary thromboembolism and deep vein thrombosis, and who presented with an acute palpable abdominal mass in hypovolemic shock. She was diagnosed with a large right abdominal wall hematoma. This is the first such case described in Korea.
CASE REPORT
An 80-year-old female had collapsed and had been found on the floor, before being diagnosed with cerebral infarction at another hospital, 2 weeks before being seen at our hospital. She had complained of left-sided paralysis with dysarthria and the Clinical manifestations commonly include acute abdominal pain and abdominal wall ecchymosis, often combined with fever and vomiting, and a decrease in hemoglobin. These compli-cations may include features of hypovolemic shock, non-pulsatile abdominal mass, local peritoneal irritation signs, and abdominal compartment syndrome. [5, 10] LMWH is increasingly being used in both community and hospital settings to initiate anticoagulation for many clinical conditions, ischemic heart disease, deep vein thrombosis, and pulmonary emboli as well as for prophylaxis following hip and knee replacement surgery. [11] LMWH, which is a derivative of standard heparin, has an affinity for factor X and a high bioavailability, which allows patients to maintain therapeutic drug levels with subcutaneous injections once or twice/daily. [12] LMWH is at least as effective as unfractionated heparin and better than unfractionated heparin for reducing the risk of major bleeding and mortality. [13] LMWH injections into the abdomen can directly damage the ab- 
